Inc () CEO Charles Theuer tells Proactive the San Diego-based biotech has named Saundra Pelletier, who currently heads up (), as a new board director.
Theuer says Pelletier is currently leading that firm's effort to bring Phexxi, a new, non-hormonal contraceptive candidate, to women and will help TRACON with its expected commercial launch of its sarcoma therapy in 2023.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE